Browse RORC

Summary
SymbolRORC
NameRAR-related orphan receptor C
Aliases RZRG; RORG; NR1F3; TOR; RZR-GAMMA; RAR-related orphan nuclear receptor variant 2; nuclear receptor RZR-gamma ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00104 Ligand-binding domain of nuclear hormone receptor
PF00105 Zinc finger
Function

Nuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5'-AGGTCA-3' preceded by a short A-T-rich sequence. Key regulator of cellular differentiation, immunity, peripheral circadian rhythm as well as lipid, steroid, xenobiotics and glucose metabolism (PubMed:19381306, PubMed:19965867, PubMed:22789990, PubMed:26160376, PubMed:20203100). Considered to have intrinsic transcriptional activity, have some natural ligands like oxysterols that act as agonists (25-hydroxycholesterol) or inverse agonists (7-oxygenated sterols), enhancing or repressing the transcriptional activity, respectively (PubMed:19965867, PubMed:22789990). Recruits distinct combinations of cofactors to target gene regulatory regions to modulate their transcriptional expression, depending on the tissue, time and promoter contexts. Regulates the circadian expression of clock genes such as CRY1, ARNTL/BMAL1 and NR1D1 in peripheral tissues and in a tissue-selective manner. Competes with NR1D1 for binding to their shared DNA response element on some clock genes such as ARNTL/BMAL1, CRY1 and NR1D1 itself, resulting in NR1D1-mediated repression or RORC-mediated activation of the expression, leading to the circadian pattern of clock genes expression. Therefore influences the period length and stability of the clock. Involved in the regulation of the rhythmic expression of genes involved in glucose and lipid metabolism, including PLIN2 and AVPR1A (PubMed:19965867). Negative regulator of adipocyte differentiation through the regulation of early phase genes expression, such as MMP3. Controls adipogenesis as well as adipocyte size and modulates insulin sensitivity in obesity. In liver, has specific and redundant functions with RORA as positive or negative modulator of expression of genes encoding phase I and Phase II proteins involved in the metabolism of lipids, steroids and xenobiotics, such as SULT1E1. Also plays also a role in the regulation of hepatocyte glucose metabolism through the regulation of G6PC and PCK1 (PubMed:19965867). Regulates the rhythmic expression of PROX1 and promotes its nuclear localization (PubMed:19381306, PubMed:19965867, PubMed:22789990, PubMed:26160376, PubMed:20203100). Plays an indispensable role in the induction of IFN-gamma dependent anti-mycobacterial systemic immunity (PubMed:26160376). ; FUNCTION: Isoform 2: Essential for thymopoiesis and the development of several secondary lymphoid tissues, including lymph nodes and Peyer's patches. Required for the generation of LTi (lymphoid tissue inducer) cells. Regulates thymocyte survival through DNA-binding on ROREs of target gene promoter regions and recruitment of coactivaros via the AF-2. Also plays a key role, downstream of IL6 and TGFB and synergistically with RORA, for lineage specification of uncommitted CD4(+) T-helper (T(H)) cells into T(H)17 cells, antagonizing the T(H)1 program. Probably regulates IL17 and IL17F expression on T(H) by binding to the essential enhancer conserved non-coding sequence 2 (CNS2) in the IL17-IL17F locus. May also play a role in the pre-TCR activation cascade leading to the maturation of alpha/beta T-cells and may participate in the regulation of DNA accessibility in the TCR-J(alpha) locus.

> Gene Ontology
 
Biological Process GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002287 alpha-beta T cell activation involved in immune response
GO:0002292 T cell differentiation involved in immune response
GO:0002293 alpha-beta T cell differentiation involved in immune response
GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0005996 monosaccharide metabolic process
GO:0006006 glucose metabolic process
GO:0006109 regulation of carbohydrate metabolic process
GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0006805 xenobiotic metabolic process
GO:0007159 leukocyte cell-cell adhesion
GO:0007623 circadian rhythm
GO:0008202 steroid metabolic process
GO:0009410 response to xenobiotic stimulus
GO:0009755 hormone-mediated signaling pathway
GO:0010675 regulation of cellular carbohydrate metabolic process
GO:0010906 regulation of glucose metabolic process
GO:0019216 regulation of lipid metabolic process
GO:0019218 regulation of steroid metabolic process
GO:0019318 hexose metabolic process
GO:0030098 lymphocyte differentiation
GO:0030217 T cell differentiation
GO:0030522 intracellular receptor signaling pathway
GO:0032922 circadian regulation of gene expression
GO:0035710 CD4-positive, alpha-beta T cell activation
GO:0036314 response to sterol
GO:0036315 cellular response to sterol
GO:0042093 T-helper cell differentiation
GO:0042110 T cell activation
GO:0042752 regulation of circadian rhythm
GO:0042753 positive regulation of circadian rhythm
GO:0043367 CD4-positive, alpha-beta T cell differentiation
GO:0043401 steroid hormone mediated signaling pathway
GO:0044262 cellular carbohydrate metabolic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0045165 cell fate commitment
GO:0045444 fat cell differentiation
GO:0045598 regulation of fat cell differentiation
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0048511 rhythmic process
GO:0048545 response to steroid hormone
GO:0060612 adipose tissue development
GO:0060850 regulation of transcription involved in cell fate commitment
GO:0061448 connective tissue development
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071383 cellular response to steroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071466 cellular response to xenobiotic stimulus
GO:0071593 lymphocyte aggregation
GO:0072538 T-helper 17 type immune response
GO:0072539 T-helper 17 cell differentiation
Molecular Function GO:0003707 steroid hormone receptor activity
GO:0004879 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding
GO:0005496 steroid binding
GO:0008142 oxysterol binding
GO:0032934 sterol binding
GO:0098531 transcription factor activity, direct ligand regulated sequence-specific DNA binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04710 Circadian rhythm
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-168256: Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-383280: Nuclear Receptor transcription pathway
R-HSA-449147: Signaling by Interleukins
Summary
SymbolRORC
NameRAR-related orphan receptor C
Aliases RZRG; RORG; NR1F3; TOR; RZR-GAMMA; RAR-related orphan nuclear receptor variant 2; nuclear receptor RZR-gamma ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RORC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between RORC and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26785144Kidney CarcinomaInhibit immunityThese findings suggest that synthetic agonists of RORĪ³t should activate TC17/TH17 cells (with concomitant reduction in the Tregs population), repress PD-1, and produce IL17 in situ (a factor associated with good prognosis in cancer).
23241743colon carcinomaInhibit immunityIndeed, ablation of the RORgammat gene in Foxp3(+) cells in polyp-prone mice stabilized T(reg) anti-inflammatory functions, suppressed inflammation, improved polyp-specific immune surveillance, and severely attenuated polyposis.
Summary
SymbolRORC
NameRAR-related orphan receptor C
Aliases RZRG; RORG; NR1F3; TOR; RZR-GAMMA; RAR-related orphan nuclear receptor variant 2; nuclear receptor RZR-gamma ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RORC in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRORC
NameRAR-related orphan receptor C
Aliases RZRG; RORG; NR1F3; TOR; RZR-GAMMA; RAR-related orphan nuclear receptor variant 2; nuclear receptor RZR-gamma ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RORC in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3770.532
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2150.826
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4730.551
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.8660.213
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3070.836
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.5740.39
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6270.51
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5620.676
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4990.724
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.1180.365
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.2690.478
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0170.952
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RORC in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.45.51.90.66
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.46.80.61
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.511.8-2.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)862516.78.31
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.97.40.51
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRORC
NameRAR-related orphan receptor C
Aliases RZRG; RORG; NR1F3; TOR; RZR-GAMMA; RAR-related orphan nuclear receptor variant 2; nuclear receptor RZR-gamma ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RORC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRORC
NameRAR-related orphan receptor C
Aliases RZRG; RORG; NR1F3; TOR; RZR-GAMMA; RAR-related orphan nuclear receptor variant 2; nuclear receptor RZR-gamma ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RORC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RORC.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRORC
NameRAR-related orphan receptor C
Aliases RZRG; RORG; NR1F3; TOR; RZR-GAMMA; RAR-related orphan nuclear receptor variant 2; nuclear receptor RZR-gamma ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RORC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRORC
NameRAR-related orphan receptor C
Aliases RZRG; RORG; NR1F3; TOR; RZR-GAMMA; RAR-related orphan nuclear receptor variant 2; nuclear receptor RZR-gamma ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RORC expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRORC
NameRAR-related orphan receptor C
Aliases RZRG; RORG; NR1F3; TOR; RZR-GAMMA; RAR-related orphan nuclear receptor variant 2; nuclear receptor RZR-gamma ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RORC and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRORC
NameRAR-related orphan receptor C
Aliases RZRG; RORG; NR1F3; TOR; RZR-GAMMA; RAR-related orphan nuclear receptor variant 2; nuclear receptor RZR-gamma ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RORC collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.